Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


      © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Tazobactam

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Active Pharmaceutical Ingredients  TAJ PHARMACEUTICALS LIMITED
   
   PRODUCT LIST
   Home
   API
   Pharmaceuticals API List >>
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 
taj packing



 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 




 

 












 



 

 
HOME >> Pharmaceuticals API List 4 >> Tazobactam

Tazobactam
 
Tazobactam pdf api



Systematic (IUPAC) name


(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide

Identifiers

CAS number 89786-04-9
ATC code J01CG02
PubChem ?
DrugBank EXPT03012

Chemical data

Formula C10H12N4O5S
Mol. mass 300.289 g/mol
Molecular Formula C10H11N4NaO5S
Molecular Weight 322.27

Indications and Usage

Treatment of moderate to severe infections caused by -resistant /tazobactam-susceptible, β-lactamase producing strains of microorganisms in the following conditions: appendicitis ( complicated by rupture or abscess); uncomplicated and complicated skin and skin structure infections; postpartum endometritis or pelvic inflammatory disease; community-acquired pneumonia (moderate severity only); nosocomial pneumonia (moderate to severe).


Dosage and Administration

Administer by IV infusion over 30 min.
Nosocomial Pneumonia
Adults

IV Start with 4.5 g every 6 h plus an aminoglycoside (administered separately) for 7 to 14 days.
Healthy Renal Function (CrCl 90 mL/min or more)
Adults

IV 3.375 g every 6 h totaling 13.5 g ( 12 g/tazobactam 1.5 g) for 7 to 10 days.
Children 2 mo of age and older

IV  80 mg/tazobactam 10 mg per kg every 8 h. Children weighing more than 40 kg with healthy renal function should receive the adult dose.
Children with appendicitis and/or peritonitis 2 mo of age and older

IV Children between 2 and 9 mo of age –  80 mg/tazobactam 10 mg per kg every 8 h. Children 9 mo of age and older weighing up to 40 kg –  100 mg/tazobactam 12.5 mg per kg every 8 h. Children weighing more than 40 kg – Administer the adult dose.
Renal Function Impairment
Adults

IV CrCl greater than 40 mL/min – 3.375 g every 6 h (all indications), and 4.5 g every 6 h (nosocomial pneumonia). CrCl 20 to 40 mL/min – 2.25 g every 6 h (all indications), and 3.375 g every 6 h (nosocomial pneumonia). CrCl less than 20 mL/min – 2.25 g every 8 h (all indications), and 2.25 g every 6 h (nosocomial pneumonia). There are no dosage recommendations for children with renal function impairment.
Hemodialysis
Adults

IV Max dosage 2.25 g every 8 h for nosocomial pneumonia and every 12 h for other indications plus one additional dose of 0.75 g following each dialysis period.
Continuous Ambulatory Peritoneal Dialysis (CAPD)
Adults

IV 2.25 g every 8 h for nosocomial pneumonia and every 12 h for other indications.

Drug Interactions

Aminoglycosides

May form microbiologically inactive complexes and should not be mixed in the same container.
Anticoagulants/Heparin

Frequently monitor coagulation parameters.
Methotrexate

May reduce Cl of methotrexate.
Probenecid

Increases and prolongs t ½ of penicillin levels.
Vecuronium

Neuromuscular blockade may be prolonged.
Incompatibility

Ringer's lactate solution.

Patient Information

* Advise patient or caregiver that medication will be prepared by health care provider and administered in a health care setting.
* Review dosing schedule and prescribed length of therapy with patient. Advise patient that dose, dosing frequency, and duration of therapy are dependent on site of infection, severity of infection, and response to treatment.
* Advise patient or caregiver to immediately inform health care provider if injection-site pain or redness, skin rash, hives, itching, or shortness of breath occur during treatment.
* Advise patient or caregiver to report the following signs of superinfection to health care provider: black “furry” tongue, foul-smelling stools, vaginal itching or discharge, white patches in mouth.
* Warn patient or caregiver that diarrhea containing blood or pus may be a sign of a serious disorder and, if noted after discharge, to seek medical care and not treat at home.

                        
PDF DOWNLOAD           WORD DOCUMENT

Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  


Taj pharmaceuticals API Logo
     

Tazobactam

New Chemicals at Taj Pharmaceuticals Ltd.

Ceftizoxime Sodium

Cefotaxime Sodium

Cefuroxime Sodium

Cefixime

Cefalexin

Betalactams Piperacillin

Meropenem

Tazobactam

Cefazolin Sodium

Cefuroxime Sodium

Cefoxitin Sodium

Cefotetan Sodium

Cefotaxime Sodium

Cefoperazone Sodium

Ceftizoxime Sodium

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.